Abstract:Acetylcholinesterase (AChE) inhibitors such as donepezil, galantamine and rivastigmine are used for the management of dementia in Alzheimer's Disease (AD). These drugs elevate endogenous acetylcholine (ACh) levels at the M1 muscarinic receptor in the brain to achieve therapeutic benefits. However, their side effects, such as nausea, vomiting, dizziness, insomnia, loss of appetite, altered heart rate, etc., are related to non-specific peripheral activation of M2-M5 muscarinic subtypes. It is logical, therefore, to develop drugs that selectively activate brain M1 receptors. Unfortunately, the orthosteric site homology among the receptor subtypes does not permit this approach. An alternative approach is to use positive allosteric modulator (PAM) of M1 receptors like benzyl quinolone carboxylic acid (BQCA). PAMs although devoid of M1 agonist activity, however, when bound, enhance the binding affinity of orthosteric ligand, Ach. The current challenge with PAMS is their low brain half-life, permeability, and higher elimination rates. This study reports active targeting of brain M1 receptors using surface modified nano lipid-drug conjugates (LDC) of M1 PAM, BQCA, to treat AD. Polysorbate-80 (P-80) surface modified stearylamine (SA)-BQCA conjugated nanoparticles (BQCA-SA-P80-NPs) were prepared by conjugating BQCA to SA, followed by the formation of nanoparticles (NPs) using P-80 by solvent injection method. The BQCA-SA-P80-NPs are near-spherical with a particle size (PS) of 166.62 ± 1.24 nm and zeta potential (ZP) of 23.59 ± 0.37 mV. In the in vitro cytotoxicity (SH-SY5Y cells) and hemolysis assays, BQCA-SA-P80-NPs, show acceptable safety and compatibility. In mice, Alzheimer's model, BQCA-SA-P80-NPs significantly prevent STZ induced changes in memory, neuronal Aβ1-42, p-Tau, APP, NF-κB, and BACE levels and neuronal cell death, when compared to untreated disease control and naïve BQCA treated group. Further, BQCA-SA-P80-NPs significantly improve the therapeutic efficacy of AChE inhibitor, donepezil (DPZ), indicating its potentiating effects. In vivo biodistribution studies in mice show selective accumulation of BQCA-SA-P80-NPs in the brain, suggesting an improved brain bioavailability and reduced peripheral side effects of BQCA. The study results demonstrate that BQCA-SA-P80-NPs can improve brain bioavailability and therapeutic efficacy of BQCA in AD.

Poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate)-based microspheres as a sustained platform for Huperzine A delivery for alzheimer's disease therapy

Preparation and in vitro and in vivo evaluation of HupA PLGA microsphere.

Poly(lactic-co-glycolic acid) microspheres for the controlled release of huperzine A: in vitro and in vivo studies and the application in the treatment of the impaired memory of mice.

Preparation Andin Vivo Evaluation of Huperzine A-loaded PLGA Microspheres

Preparation of Huperzine-a-loaded Microspheres and Studies on Its Pharmacokinetics and Pharmacodynamics in Rats

Hierarchical Adhesive Hydrogel Microparticles with Galantamine Hydrobromide Encapsulation for Alzheimer’s Disease

Huperzine A As Potential Treatment Of Alzheimer'S Disease: An Assessment On Chemistry, Pharmacology, And Clinical Studies

Preparation, Optimization and Characteristic of Huperzine A Loaded Nanostructured Lipid Carriers

The development of a novel and powerful biosynthesis platform for expressing huperzine A for the Alzheimer's disease

Prolonged effects of poly(lactic-co-glycolic acid) microsphere-containing huperzine A on mouse memory dysfunction induced by scopolamine.

Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine

Effects of Formulation Factors on Encapsulation Efficiency and Release Behaviour in Vitro of Huperzine A-Plga Microspheres

Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimer's Disease

Highly Branched Poly(β-Amino Ester) Delivery of Minicircle DNA for Transfection of Neurodegenerative Disease Related Cells

Inhibiting Β-Amyloid-associated Alzheimer’s Pathogenesis in Vitro and in Vivo by a Multifunctional Dimeric Bis(12)-hupyridone Derived from Its Natural Analogue

3-Hydroxybutyrate Methyl Ester As a Potential Drug Against Alzheimer's Disease Via Mitochondria Protection Mechanism.

Inhibition of Aβ Aggregation and Tau Phosphorylation with Functionalized Biomimetic Nanoparticles for Synergic Alzheimer’s Disease Therapy

O4‐04–06: Huperzine A for Alzheimer's Disease

Polysorbate-80 surface modified nano-stearylamine BQCA conjugate for the management of Alzheimer's disease

Five novel and highly efficient endophytic fungi isolated from Huperzia serrata expressing huperzine A for the treatment of Alzheimer’s disease

Dissolving microneedles for transdermal delivery of huperzine A for the treatment of Alzheimer's disease